Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials
BackgroundIn recent years, immune checkpoint inhibitors (ICIs) had extremely rapid growth in anti-cancer and improved outcomes of many malignancies, specifically lung cancer. However, the incidence of ICIs-related adverse events also raised. Using this meta-analysis, ICIs-related respiratory disorde...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1115305/full |
| _version_ | 1797893770636689408 |
|---|---|
| author | Han Liu Sean X. Luo Jing Jie Liping Peng Shuai Wang Lei Song |
| author_facet | Han Liu Sean X. Luo Jing Jie Liping Peng Shuai Wang Lei Song |
| author_sort | Han Liu |
| collection | DOAJ |
| description | BackgroundIn recent years, immune checkpoint inhibitors (ICIs) had extremely rapid growth in anti-cancer and improved outcomes of many malignancies, specifically lung cancer. However, the incidence of ICIs-related adverse events also raised. Using this meta-analysis, ICIs-related respiratory disorders were investigated in lung cancer patients.MethodsUsing Cochrane Library, Embase, and PubMed databases, we performed an integrated search for randomized controlled trials (RCTs) to compare respiratory disorders among different regimens. The data was prepared with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guideline, and the quality of included studies was evaluated based on the Cochrane manual.ResultsIn total, 22 RCTs were involved in this meta-analysis. Compared with ICIs, chemotherapy reduced the risk of interstitial lung disease (p = 0.03; SMD: 2.81; 95% CI: 1.08, 7.27), pleural effusion (p = 0.002; SMD: 2.12; 95% CI: 1.32, 3.42), and pneumonitis (p < 0.00001; SMD: 9.23; 95% CI: 4.57, 18.64). ICIs plus chemotherapy could provide a higher probability for patients to suffer pneumonitis than chemotherapy (p = 0.01; SMD: 1.96; 95% CI: 1.17, 3.28). In addition, single ICI brought a lower likelihood for patients suffering pneumonitis than double ICIs (p = 0.004; SMD: 2.17; 95% CI: 1.27, 3.69).ConclusionICIs-based treatment, such as ICIs alone, ICIs plus chemotherapy and double ICIs, can raise the incidences of some respiratory disorders in patients with lung cancer. It suggests that ICIs should be conducted based on a comprehensive consideration to prevent ICIs-related respiratory disorders. To a certain degree, this study might be provided to the clinician as a reference for ICIs practice.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022378901, identifier (CRD42022378901). |
| first_indexed | 2024-04-10T06:58:10Z |
| format | Article |
| id | doaj.art-500265b050404487a2b402ff55ab2162 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T06:58:10Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-500265b050404487a2b402ff55ab21622023-02-28T05:48:51ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-02-011410.3389/fimmu.2023.11153051115305Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trialsHan Liu0Sean X. Luo1Jing Jie2Liping Peng3Shuai Wang4Lei Song5Department of Respiratory Medicine, The First Hospital of Jilin University, Changchun, Jilin, ChinaDepartment of Vascular Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin, ChinaDepartment of Respiratory Medicine, The First Hospital of Jilin University, Changchun, Jilin, ChinaDepartment of Respiratory Medicine, The First Hospital of Jilin University, Changchun, Jilin, ChinaDepartment of Vascular Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin, ChinaDepartment of Respiratory Medicine, The First Hospital of Jilin University, Changchun, Jilin, ChinaBackgroundIn recent years, immune checkpoint inhibitors (ICIs) had extremely rapid growth in anti-cancer and improved outcomes of many malignancies, specifically lung cancer. However, the incidence of ICIs-related adverse events also raised. Using this meta-analysis, ICIs-related respiratory disorders were investigated in lung cancer patients.MethodsUsing Cochrane Library, Embase, and PubMed databases, we performed an integrated search for randomized controlled trials (RCTs) to compare respiratory disorders among different regimens. The data was prepared with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guideline, and the quality of included studies was evaluated based on the Cochrane manual.ResultsIn total, 22 RCTs were involved in this meta-analysis. Compared with ICIs, chemotherapy reduced the risk of interstitial lung disease (p = 0.03; SMD: 2.81; 95% CI: 1.08, 7.27), pleural effusion (p = 0.002; SMD: 2.12; 95% CI: 1.32, 3.42), and pneumonitis (p < 0.00001; SMD: 9.23; 95% CI: 4.57, 18.64). ICIs plus chemotherapy could provide a higher probability for patients to suffer pneumonitis than chemotherapy (p = 0.01; SMD: 1.96; 95% CI: 1.17, 3.28). In addition, single ICI brought a lower likelihood for patients suffering pneumonitis than double ICIs (p = 0.004; SMD: 2.17; 95% CI: 1.27, 3.69).ConclusionICIs-based treatment, such as ICIs alone, ICIs plus chemotherapy and double ICIs, can raise the incidences of some respiratory disorders in patients with lung cancer. It suggests that ICIs should be conducted based on a comprehensive consideration to prevent ICIs-related respiratory disorders. To a certain degree, this study might be provided to the clinician as a reference for ICIs practice.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022378901, identifier (CRD42022378901).https://www.frontiersin.org/articles/10.3389/fimmu.2023.1115305/fullimmune checkpoint inhibitors (ICI)respiratory disorderslung cancermeta-analysisrandomized controlled trials (RCT) |
| spellingShingle | Han Liu Sean X. Luo Jing Jie Liping Peng Shuai Wang Lei Song Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials Frontiers in Immunology immune checkpoint inhibitors (ICI) respiratory disorders lung cancer meta-analysis randomized controlled trials (RCT) |
| title | Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials |
| title_full | Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials |
| title_fullStr | Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials |
| title_full_unstemmed | Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials |
| title_short | Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials |
| title_sort | immune checkpoint inhibitors related respiratory disorders in patients with lung cancer a meta analysis of randomized controlled trials |
| topic | immune checkpoint inhibitors (ICI) respiratory disorders lung cancer meta-analysis randomized controlled trials (RCT) |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1115305/full |
| work_keys_str_mv | AT hanliu immunecheckpointinhibitorsrelatedrespiratorydisordersinpatientswithlungcancerametaanalysisofrandomizedcontrolledtrials AT seanxluo immunecheckpointinhibitorsrelatedrespiratorydisordersinpatientswithlungcancerametaanalysisofrandomizedcontrolledtrials AT jingjie immunecheckpointinhibitorsrelatedrespiratorydisordersinpatientswithlungcancerametaanalysisofrandomizedcontrolledtrials AT lipingpeng immunecheckpointinhibitorsrelatedrespiratorydisordersinpatientswithlungcancerametaanalysisofrandomizedcontrolledtrials AT shuaiwang immunecheckpointinhibitorsrelatedrespiratorydisordersinpatientswithlungcancerametaanalysisofrandomizedcontrolledtrials AT leisong immunecheckpointinhibitorsrelatedrespiratorydisordersinpatientswithlungcancerametaanalysisofrandomizedcontrolledtrials |